Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Podcast – How I went from accountancy to NPS research trailblazer

In the first episode of series three of A Coffee With…, MPharm programme director at Swansea University Amira Guirguis reveals how she worked her way up in pharmacy after moving to the UK from Egypt.

Ms Guirguis is now an internationally renowned expert in novel psychoactive substances (NPS) – also referred to as “legal highs”.

But her career path is somewhat unconventional. In Egypt, where she grew up, she missed the entry requirement for pharmacy school by just 0.5%, which at first shattered her dream of pursuing pharmacy.

After a career in accountancy, Ms Guirguis relocated to the UK aged 32. This new beginning also offered her the opportunity of re-training with a degree in pharmacy.

It was during her undergraduate years that “the research bug” hit her, she tells C+D’s reporter Emily Stearn in a podcast (listen below).



Ms Guirguis worked in community pharmacy for a few years but it was while working in the hospital sector that she first encountered patients using legal highs. She realised that she knew nothing about them and neither, it seemed, did anyone else.

“We say we are the medicine experts. Yet there are loads and loads of medicines like NPS sold online openly, and we don’t really know much about [them]. That’s actually what triggered me to start working in this area,” she says.

As her expertise on NPS grew, so did her profile. From initially collaborating with the Royal Pharmaceutical Society, she has since established the first Home Office-licensed pharmacist-led drug-checking service in the UK and has been called upon in several high-profile legal cases.

Having such a crucial role in the establishment of the drug-checking service – which was initially piloted in 2019 before being rolled out nationally – was “amazing”, Ms Guirguis says. Working with the police, Home Office, a substance misuse clinic, and relevant stakeholders, she was able to put her research into practice, making it “directly relevant to patients”.

However, the new service was met with some controversy. “Not a lot of people feel it is something that should be done, should be funded, or should be paid for by the taxpayers,” she says. People questioned whether the service would encourage rather than help prevent illicit drug use.

But now a leader in her field, she is currently leading a programme on the service at Swansea University, where she began passing on her learning to the first intake of students in September 2021.


Listen to the podcast to find out more about:

  • Why she chose to move to the UK and begin her dream of studying pharmacy
  • How she tackled the “controversy” surrounding the first Home Office-licensed pharmacist-led drug-checking service in the UK
  • Not being afraid of trying different things
  • How she is implementing a “modern approach” as MPharm programme director at Swansea University


You can listen to the podcast above. Alternatively, follow C+D's podcasts by searching “Chemist+Druggist podcast” on your preferred app or on Soundcloud


Yeovil, Winchester & Dorchester
£50-55,000 per annum

Apply Now
Latest News & Analysis
See All



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts